Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS. Durkacz said the therapy is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments.
Durkacz also discussed Quantum BioPharma's commercial alcohol metabolism product, unbuzzd(TM), which is designed to accelerate blood alcohol metabolism and is currently available in the U.S. market. Looking ahead, he highlighted the company's upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in multiple sclerosis patients following Phase 1 testing in healthy volunteers.
The company's lead compound, Lucid-MS, is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. This represents a significant opportunity as current treatments primarily focus on symptom management rather than addressing the root cause of nerve damage. Quantum BioPharma's approach could potentially fill a critical gap in MS therapy.
Regarding unbuzzd(TM), Quantum BioPharma retains a 19.84% ownership stake in Unbuzzd Wellness Inc. as of March 31, 2026, along with royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once that threshold is reached, the royalty drops to 3% in perpetuity. This structure provides a recurring revenue stream that could support further research and development efforts.
The company's dual focus on both a high-potential drug candidate and a commercial product offers a balanced risk profile. While Lucid-MS represents a high-reward opportunity with significant regulatory hurdles, unbuzzd(TM) provides near-term revenue potential and market validation. The upcoming Phase 2 trial will be a critical milestone for Lucid-MS, with results potentially shaping the company's future trajectory.
For more details, the full press release is available at https://ibn.fm/HURxt. Additional information about Quantum BioPharma can be found in the company's newsroom at https://ibn.fm/QNTM.
